Pathophysiology of Acute Kidney Injury in Patients with COVID-19

Acute kidney injury (AKI) is common among hospitalized patients with Coronavirus Infectious Disease 2019 (COVID-19), with the occurrence of AKI ranging from 0 5% to 80% The variability in the occurrence of AKI has been attributed to the difference in geographic locations, race/ethnicity, and severity of illness AKI among hospitalized patients is associated with increased length of stay and in-hospital deaths Even patients with AKI who survive to hospital discharge are at risk of developing chronic kidney disease (CKD) or end-stage kidney disease (ESKD) An improved knowledge of the pathophysiology of AKI in COVID-19 is crucial to mitigate and manage AKI and to improve the survival of patients who developed AKI during COVID-19 The goal of this article is to provide our current understanding of the etiology and the pathophysiology of AKI in the setting of COVID-19